<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01248611</url>
  </required_header>
  <id_info>
    <org_study_id>NFCP1-2010</org_study_id>
    <nct_id>NCT01248611</nct_id>
  </id_info>
  <brief_title>Nasal Fentanyl for Patient Controlled Treatment of Pain in Cancer</brief_title>
  <acronym>NFCP1-2010</acronym>
  <official_title>Nasal Fentanyl for Patient Controlled Treatment of Pain in Cancer An Open Label Prospective Phase I b Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Olavs Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traditionally cancer pain is treated with long acting opioids such as morphine around the&#xD;
      clock. However, there is no evidence that all patients have a stable pain requiring around&#xD;
      the clock medication. So far opioids for self-administration with a rapid onset of action&#xD;
      have not been available. Recently a nasal formulation of fentanyl (an opioid similar to&#xD;
      morphine) was released in Europe for treatment of breakthrough pain, i.e. an unpredictable&#xD;
      pain with short duration that breaks through the otherwise stable pain controlled with the&#xD;
      around the clock medication. The basic idea is that this formulation may open for patient&#xD;
      controlled analgesia of chronic cancer pain, due to the ultra rapid onset of action of&#xD;
      nasally delivered fentanyl. This means that the patient only takes medication when in pain.&#xD;
      This single center feasibility / safety study is the first part of a study to investigate&#xD;
      this alternative cancer pain treatment approach.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sedation/drowsiness</measure>
    <time_frame>10 days</time_frame>
    <description>scores on a 0-10 numerical rating scale; 0=none / 10=intolerable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>nausea and vomiting</measure>
    <time_frame>10 days</time_frame>
    <description>nausea scores on a 0-10 numerical rating scale; 0=none / 10=intolerable vomiting yes/no</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain intensity</measure>
    <time_frame>10 days</time_frame>
    <description>scores on a 0-10 numerical rating scale; 0=none / 10=intolerable</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Chronic Pain</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>fentanyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cancer patients with pain</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fentanyl</intervention_name>
    <description>nasally, dose titrated to effect</description>
    <arm_group_label>fentanyl</arm_group_label>
    <other_name>Instanyl (nNcomed Pharma)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Cancer patients with metastatic disease&#xD;
&#xD;
          2. Adult (older than 18 years)&#xD;
&#xD;
          3. Life expectancy of &gt; 3 months&#xD;
&#xD;
          4. Cancer-related pain &gt; 3 on an 11 point Numerical Rating Scale (NRS)&#xD;
&#xD;
          5. In the need of opioids (step II or III)&#xD;
&#xD;
          6. Able to use nasal drugs.&#xD;
&#xD;
          7. Women of child bearing potential using adequate contraception&#xD;
&#xD;
          8. Informed consent given according to applicable requirements before any trial-related&#xD;
             activities. Trial-related activities are any procedure that would not have been&#xD;
             performed during the routine management of the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of substance abuse&#xD;
&#xD;
          2. Cognitive impairment which makes the patient unable to complete questionnaires or not&#xD;
             able to comply with the study procedures&#xD;
&#xD;
          3. Treated with MAO inhibitor within the last 14 days&#xD;
&#xD;
          4. Known hypersensitivity to study drug or specific contraindications to the study drug&#xD;
&#xD;
          5. Nasopharyngeal device such as gastric tube&#xD;
&#xD;
          6. Concomitant participation in any other trials dealing with pain with an&#xD;
             investigational drug or device apart from cancer treatment within 14 days prior to&#xD;
             inclusion in this trial&#xD;
&#xD;
          7. Pathological conditions of the nasal cavity as contraindication to nasal fentanyl&#xD;
&#xD;
          8. Sleep apnoea syndrome&#xD;
&#xD;
          9. Pregnant or breastfeeding women&#xD;
&#xD;
         10. Psychiatric disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stein Kaasa, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St.Olav's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St.Olavs University Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Thron√¶s M, Kaasa S, Dale O. A pilot study of nasal fentanyl for patient controlled treatment of cancer pain. J Opioid Manag. 2014 Jan-Feb;10(1):21-8. doi: 10.5055/jom.2014.0188.</citation>
    <PMID>24604566</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>November 18, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <last_update_submitted>May 9, 2014</last_update_submitted>
  <last_update_submitted_qc>May 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>adverse effects</keyword>
  <keyword>safety</keyword>
  <keyword>feasibility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

